Results 171 to 180 of about 111,549 (295)

HLA ANTIGEN EXPRESSION IN MYOSITIS

The Lancet, 1985
Isenberg, D, Rowe, D, Beverley, P
openaire   +4 more sources

Harnessing chimeric antigen receptor macrophages against solid tumors

Cancer Communications, EarlyView.
Abstract Macrophages are prevalent in multiple tumors and exhibit diverse and potent functional activities. Therapeutic reprogramming of macrophage phenotypes represents a promising strategy for cancer immunotherapy. Engineering chimeric antigen receptors (CARs) to endow macrophages with anti‐tumor capacities demonstrated encouraging efficacy ...
Mengru Wang, Zhen Qin, Xiu‐Wu Bian, Yu Shi   +3 more
wiley   +1 more source

MHCquant2 refines immunopeptidomics tumor antigen discovery. [PDF]

Genome Biol
Scheid J, Lemke S, Hoenisch-Gravel N, Dengler A, Sachsenberg T, Declerq A, Gabriels R, Bauer J, Wacker M, Bichmann L, Martens L, Dubbelaar ML, Nahnsen S, Walz JS.   +13 more
europepmc   +1 more source

Sensitization of human lymphocytes in vitro: genetic restriction of secondary T cell responses is dictated by the HLA-DR phenotype of antigen-presenting cells. [PDF]

, 1982
Dennis Ford, Anne S. Hamblin, Denis R. Burger   +2 more
openalex   +1 more source

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

Clinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni, Chin Hang Yiu, Mohammad A. Ali, Christine Y. Lu   +3 more
wiley   +1 more source

Analyses of HLA antigens, especially HLA-A and -B interlocus antigen, on platelets with monoclonal antibodies and elisa assay.

, 1987
Yoshisuke Nose, Nobuo Araki, Hiroji Yamahira, Junya Shimizu, Kaoru Sato, Takako Nakatsuji, Kimiyoshi Tsuji, Kazuo Ōno   +7 more
openalex   +2 more sources

Skeletal muscle expression of class II histocompatibility antigens (HLA-DR) in polymyositis and other muscle disorders with an inflammatory infiltrate. [PDF]

, 1988
J A Zuk, Ashley A. Fletcher
openalex   +1 more source

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta‐Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
Sacituzumab govitecan (SG), a humanized antibody‐drug conjugate, enables intra‐tumor delivery of SN‐38, the active metabolite of irinotecan, with the aim of increasing efficacy. SN‐38 is predominantly inactivated by the polymorphically expressed uridine diphosphate glucuronosyltransferase 1A1 (UGT1AA) where reduced activity can lead to toxicity.
Cinzia Dello Russo, Innocent Gerald Asiimwe, Sudeep Pushpakom, Carlo Palmieri, Munir Pirmohamed   +4 more
wiley   +1 more source

Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma. [PDF]

Cancer Immunol Immunother
Lutz J, Feist RK, Sonntag T, Peguero-Sánchez E, Wolter K, Bick R, Bauer J, Walz JS, Heidenreich R.   +8 more
europepmc   +1 more source

Hla antigens in whipple's disease

, 1987
Dobbins William O.
openalex   +1 more source